Key result
Perivascular chymotrypsin microinjection induces abdominal aortic aneurysms in 100% of mice vs. 0% with PBS.
Why the study?
Existing murine abdominal aortic aneurysm models are limited by technical complexity, prolonged operative time, or incomplete recapitulation of human pathology, creating a need for a reliable and technically accessible animal model.
Does direct perivascular sheath microinjection of chymotrypsin reliably induce abdominal aortic aneurysm with human-like pathological features in mice compared with PBS and topical PPE controls?
Does direct perivascular sheath microinjection of chymotrypsin reliably induce abdominal aortic aneurysm with human-like pathological features in mice compared with PBS and topical PPE controls?
Provides a technically streamlined, reproducible murine abdominal aortic aneurysm model using perivascular sheath microinjection of 0.25% chymotrypsin with 100% induction at day 14, avoiding arteriotomy or complex microsurgery.
Answers are grounded in this paper and cite their sources.
New murine AAA model may streamline preclinical studies; leaves open validation against human pathology and existing platforms.
Abdominal aortic aneurysm (AAA) is a life-threatening degenerative vascular disease for which no effective pharmacological therapy currently exists. Reliable and technically accessible animal models are essential for mechanistic and preclinical investigations. However, existing murine platforms are limited by technical complexity, prolonged operative time, or incomplete recapitulation of human AAA pathology. Here, this study presents a novel murine AAA model established by direct perivascular sheath microinjection of chymotrypsin. After midline laparotomy and identification of the infrarenal abdominal aorta, chymotrypsin working solution is injected directly into the perivascular sheath space under direct vision using a microscale needle. To determine the optimal enzyme concentration, a pilot dose-finding study was conducted using 0.125% (w/v; 1.25 mg/mL), 0.25% (w/v; 2.50 mg/mL), and 0.375% (w/v; 3.75 mg/mL) chymotrypsin (n = 5 per group), with PBS as negative control and topical PPE as positive control. Based on aneurysm incidence, aortic diameter progression, and mortality, 0.25% chymotrypsin was selected for the main study. The chymotrypsin group was directly compared with the PPE positive control group to benchmark the pathological features of this novel model. Serial Doppler ultrasonography confirmed a 100% aneurysm induction rate at day 14 in chymotrypsin-treated mice, whereas no dilation occurred in PBS-injected controls. Histological analyses revealed pronounced medial thickening, elastic fiber fragmentation, and collagen deposition, together with markedly elevated immunohistochemical expression of matrix metalloproteinase (MMP)-2 and MMP-9 in aortic sections. Quantitative morphometry demonstrated significant increases in aortic wall thickness and collagen volume fraction, and a corresponding reduction in elastic fiber content in chymotrypsin-treated animals compared with controls. This protocol thus provides a technically streamlined, highly reproducible, and translationally relevant murine AAA model. Because the procedure avoids aortic dissection, arteriotomy, or specialized microsurgical training, it is well suited to laboratories investigating aneurysm pathobiology or evaluating novel pharmacological interventions.
No takes yet. Share an insight, caveat, or question.
Shen et al. (2026) studied Abdominal aortic aneurysm (AAA) murine model. Perivascular sheath microinjection of chymotrypsin vs. PBS injection (negative control) and topical porcine pancreatic elastase (PPE, positive control) was evaluated on Aneurysm induction rate at day 14. Perivascular sheath microinjection of 0.25% chymotrypsin induced abdominal aortic aneurysms in 100% of mice at day 14 compared with 0% in PBS-injected controls.
Synapse has enriched 10 related papers. Consider them for comparative context: